Reglitazar
Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 170861-63-9
- 화학식: C22H20N2O5
- 분자량:392.40
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 3T3-L1 | EC50 |
1.1 x 10-7M
Compound: 2 (JTT-501)
|
Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
|
[PMID: 9599241] |
Chemical Information
-
CAS No. 170861-63-9
-
분자량 392.40
-
화학식 C22H20N2O5
-
SMILES
O=C(C1CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)NOC1=O
-
Synonyms
JT 501
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)